ArticleJournal of nanobiotechnology2026
Bio-hybrid nanovesicles with multimodal antioxidant and immunomodulatory functions attenuate acute kidney injury.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Oxidative stress, marked by a disparity between the generation of reactive oxygen species (ROS) and the body's antioxidant defenses, is crucial in the development of acute kidney injury (AKI), where excessive ROS accumulation drives tubular epithelial cell damage and inflammatory cascades. Dysregulated inflammatory immunity further exacerbates tissue injury, highlighting the need for integrated strategies that simultaneously regulate oxidative defense and inflammatory immune activation. Given this rationale, we developed bio-hybrid nanovesicles (ES-EVs) by integrating ES NPs of epigallocatechin-3-gallate (EGCG) and selenomethionine (SeMet) into extracellular vesicles derived from human umbilical cord mesenchymal stem cells (hUMSC-EVs). In this study, ES NPs were synthesized, preserving the biological activities of EGCG and SeMet while enhancing their stability and bioavailability. Furthermore, the integration of the potent antioxidant and anti-inflammatory properties of ES NPs with the passive targeted delivery and immunomodulatory functions of hUMSC-EVs offers a promising strategy for the treatment of AKI. In vitro evaluation confirmed that ES-EVs were able to mitigate oxidative stress, protect mitochondria, inhibit apoptosis and polarize macrophages toward an anti-inflammatory phenotype, thereby preventing excessive inflammatory cascades. In vivo experiments demonstrated that ES-EVs effectively enhanced renal function, repaired damaged renal tissue and decreased apoptosis. ES-EVs aid renal function recovery by inhibiting oxidative stress, maintaining inflammatory homeostasis and reprogramming the immune microenvironment. RNA sequencing analysis demonstrated that ES-EVs can alleviate cisplatin induced oxidative stress and DNA damage, and at the same time play an anti-inflammatory role. In summary, this study has established a bionic hybrid nanovesicular with multifunctional therapeutic properties, which lays the foundation for the clinical translation of management of AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.